Login
Navigate Fool.com
Will SNY beat
the market?

Sanofi (ADR)

NYSE: SNY

Community Rating: 4 Stars: Favorite

54.87 -0.18 (-0.33%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $55.06
Previous Close $55.05
Daily Range $54.87 - $55.86
52-Week Range $33.03 - $55.86
Market Cap $147.2B
P/E Ratio 29.60
Dividend (Yield) $1.30 (2.4%)
Ex-Dividend Date
Dividend Pay Date
05/06/13
01/01/70
Volume 798,652
Average Daily Volume 2,328,765
Current FY EPS $3.75

How do you think SNY
will perform against the market?

Top SNY Bull/Bear Pitches

 

CraigMiles (< 20)
Submitted October 30, 2011

Undervalued plus ~3% to 4% dividend.<br />The value has been tricky to estimate as the company has so much equity. If I only consider the present value of the ability to generate FCF I get a value of … More

0 Replies Reply Report this Post
 

anton123 (0)
Submitted June 25, 2009

UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir. “We have to be careful not to taint a medicine which he … More

0 Replies Reply Report this Post

News & Commentary

The 5 Highest-Paying Dividend Stocks in Big Pharma

Not all top dividend yields are backed up by strong businesses.

Another Multiple Sclerosis Winner for Biogen

Biogen submits Plegridy for FDA approval.

Regeneron and Sanofi: An Unstoppable Biotech Duo?

More positive clinical trial data released today.

Regeneron-Sanofi Asthma Drug Shows Promising Early Results

Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Glo

1 Great Dividend You Can Buy Right Now

This stocks yield may not be a jaw-dropper yet, but it's positioned "purrrrrfectly" in a rapidly growing sector to deliver long term profits and payouts.

Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Started

Biogen's MS drug is off to a hot start, and its new hemophilia drugs are under FDA review.

Too Many Questions Make This Thursday Mover a Sell

Will ASCO Unlock Big Value in This Cancer Drug Class?

With the American Society of Clinical Oncology's annual meeting less than two weeks away, see what drug class could see big gains in the wake of new abstract data.

This Week in Biotech

Clinical data and abstracts abound ahead of the American Society of Clinical Oncology's annual meeting.

See More SNY News...

Sector

Healthcare

Industry

Drugs

Sanofi (ADR) (SNY) Description

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Website: http://www.sanofi-aventis.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks